Arecor Therapeutics annual free cash flow
2022
2023
2024
2025
Arecor Therapeutics Free Cash Flow (FCF) History (AREC)
Arecor Therapeutics reported −£2.5M in free cash flow for fiscal 2025, an increase of £6.9M from the previous fiscal year, with a free cash flow margin of −143.64%.
View full Arecor Therapeutics company overviewArecor Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −£2.5M | £6.9M | — | −143.64% |
| 2024 | 2024-12-31 | −£9.3M | −£3.3M | — | −568.35% |
| 2023 | 2023-12-31 | −£6.0M | £5.1M | — | −131.03% |
| 2022 | 2022-12-31 | −£11.1M | — | — | −462.96% |
Arecor Therapeutics free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Arecor Therapeutics source filings ↗Community posts
Arecor conditionally raises £5 million to extend insulin-development funding
Arecor Therapeutics ($AREC-LSE) has conditionally placed approximately 7.35 million new shares at 68 pence each, raising about £5 million before expenses. The financing follows an accelerated bookbuild and is separate from a planned retail ...
